Tech Company Inital Public Offerings
Edgewise Therapeutics IPO
Edgewise Therapeutics, based in Boulder, went public on 3/26/2021.
Transaction Overview
Company Name
Announced On
3/26/2021
Transaction Type
IPO
Amount
$160,000,000
Proceeds Purpose
Use of proceeds for the Edgewise Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3415 Colorado Ave.
Boulder, CO 80304
USA
Boulder, CO 80304
USA
Phone
Website
Email Address
Overview
Edgewise Therapeutics is a new company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Koch
Chief Financial Officer
Michael Carruthers
Chief Medical Officer
Kirsten Gruis
Chief Scientific Officer
Alan Russell
Vice President
Abby Bronson
VP - Bus. Development
Behrad Derakhshan
VP - General Counsel
John Moore
VP - Regulatory Affairs
Nicole Kilburn
Browse more venture capital transactions:
Prev: 3/25/2021: Kubecost venture capital transaction
Next: 3/26/2021: Snapsheet venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs